EMA Authorised: Spevigo (spesolimab) — LEO Pharma A/S

View source ↗

Summary

The EMA authorised Spevigo (spesolimab) by LEO Pharma A/S for psoriasis, with conditional approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• SPEVIGO (SPESOLIMAB-SBZO)

Snippet

Status: Authorised. Therapeutic area: Psoriasis. MAH: LEO Pharma A/S. Decision date: 14/04/2026. Conditional approval